unknown
Stage
3
Investors
About
HDAX Therapeutics develops potent, selective small molecule inhibitors targeting HDAC6 for treating neurological and cardiovascular diseases, leveraging a proprietary 2-site binding mechanism.
Explore HDAX Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.